CYP3A7 and polycystic ovary syndrome: Indeed, polycystic ovary syndrome (PCOS) patients carrying the CYP3A7*1 C variant – indicative of persistent expression of CYP3A7 through to adulthood – have lower androgen concentrations than PCOS noncarrier patients [18], which may overall dampen androgen signalling pathways.